메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한정신약물학회 Clinical Psychopharmacology and Neuroscience Clinical Psychopharmacology and Neuroscience 제12권 제1호
발행연도
2014.1
수록면
1 - 7 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
As a strategy for antipsychotic treatment of schizophrenia, monotherapy is clearly optimal when both effective and tolerated. When a patient fails to respond to an adequate dose of an antipsychotic, alternatives include switching, administering a higherdose (above the licensed dose), polypharmacy or clozapine. Clozapine is the only option with established efficacy, but is lessmanageable than other antipsychotics. We therefore reviewed other options, focusing on the treatment of acute-phaseschizophrenia. According to recent evidence, an antipsychotic may be viewed as ineffective within 1-4 weeks in acute-phasepractice, although some differences may exist among antipsychotics. Whether a switching strategy is effective might dependon the initial antipsychotic and which antipsychotic is switched to. As weak evidence points toward augmentation being superiorto continuation of the initial antipsychotic, inclusion of augmentation arms in larger studies comparing strategies for earlynon-responders in the acute-phase is justified. With respect to high-doses, little evidence is available regarding acute-phasetreatment, and the issue remains controversial. Although evidence for antipsychotic switching, augmentation, and high-doseshas gradually been accumulating, more studies performed in real clinical practice with minimal bias are required to establishstrategies for early non-response to an antipsychotic drug in the treatment of acute-phase schizophrenia.

목차

등록된 정보가 없습니다.

참고문헌 (21)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0